CXCL9 and cancer: Two discovery pan-cancer datasets were used to examine the 4-chemokine signature (CCL4, CCL5, CXCL9, CXCL10; herein referred to as c-Score) as a predictive biomarker for T cell-inflammation and ICI treatment outcomes across different solid tumor types (Fig. 1).